Krystal Biotech (KRYS) EVP Laurent Goux details options, RSUs and stock
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Krystal Biotech EVP Laurent Goux has filed an initial ownership report showing equity awards and stock holdings in Krystal Biotech, Inc. The Form 3 lists several grants of stock options and restricted stock units, plus common shares, all held directly as of March 1, 2026.
Stock option positions include grants covering 9,050, 7,449, 2,367, 4,750, 2,750 and 19,000 shares of common stock. Restricted stock unit awards include 3,628, 891 and 674 units, and he directly holds 919 shares of common stock.
The footnotes state that multiple option and RSU grants vest in four equal annual installments on the first through fourth anniversaries of their grant dates in 2023, 2024, 2025 and 2026, subject to his continued service, and note that one stock option grant for 19,000 shares is fully vested.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Goux Laurent Louis Jean
Role
EVP, Head of International
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 9,050 shares (Direct);
Restricted Stock Units — 3,628 shares (Direct);
Common Stock — 919 shares (Direct)
Footnotes (1)
- The stock option was granted on February 27, 2026, and vests in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. The restricted stock units ("RSUs") vest in four equal annual installments with the first installment vesting on February 27, 2027. The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The stock option was granted on February 28, 2025, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 28, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The stock option was granted on February 29, 2024, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. The RSUs vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, February 29, 2024, subject to the Reporting Person's continued service through each applicable vesting date. The stock option was granted on February 28, 2023, and vested or will vest in four equal annual installments on each of the first, second, third, and fourth anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. The stock option is fully vested.
FAQ
What does Krystal Biotech (KRYS) EVP Laurent Goux report on this Form 3?
Laurent Goux reports his initial beneficial ownership in Krystal Biotech, Inc., including multiple stock option and restricted stock unit grants plus common shares. These holdings reflect his equity-based compensation as EVP, Head of International, all held directly as of March 1, 2026.
How many Krystal Biotech (KRYS) stock options does Laurent Goux hold?
The Form 3 lists several stock option grants for 9,050, 7,449, 2,367, 4,750, 2,750 and 19,000 shares. Each grant represents the right to buy Krystal Biotech common stock, with vesting tied to specific grant dates and continued service conditions described in the footnotes.
What restricted stock units in Krystal Biotech (KRYS) does Laurent Goux beneficially own?
Laurent Goux holds restricted stock unit awards of 3,628, 891 and 674 units. Each RSU represents a contingent right to receive one share of Krystal Biotech common stock, vesting in four equal annual installments if he remains in service through the applicable vesting dates.
What are the vesting terms for Laurent Goux’s Krystal Biotech (KRYS) equity awards?
Several stock option and RSU grants vest in four equal annual installments on the first through fourth anniversaries of grant dates in 2023, 2024, 2025 and 2026. Vesting is conditioned on Laurent Goux’s continued service with Krystal Biotech on each applicable vesting date.
Is any of Laurent Goux’s Krystal Biotech (KRYS) stock fully vested?
Yes. One stock option grant covering 19,000 shares of Krystal Biotech common stock is described as fully vested. Other option and restricted stock unit grants vest over time in equal annual installments, contingent on his continued service with the company.